Thymosin beta-4 improved the function and repair potential of diabetic endothelial cells by reducing cellular aging, boosting survival, and enhancing blood vessel formation in diabetic mice.
Angiogenic potency restoredTβ4-treated diabetic endothelial cells showed improved blood vessel formation when transplanted into diabetic mice with ischemic limb disease
What the researchers found
Thymosin beta-4 at 600 ng/mL produced multiple improvements in diabetic endothelial cells:
• Significantly upregulated AKT activity and Bcl-XL protein expression (pro-survival pathways)
• Enhanced cell viability and proliferation
• Reduced cellular senescence (aging)
• Decreased secretion of endothelin-1 (a vasoconstrictor) and MMP-1 (a tissue-degrading enzyme)
• Improved angiogenic (blood vessel-forming) potency when dia-hiPSC-ECs were used to treat ischemic limb disease in type 2 diabetic mice
However, Tβ4 did NOT improve mitochondrial membrane potential, glycine homeostasis, or reduce ICAM-1 protein expression — showing its effects are specific to certain pathways rather than a universal fix for diabetic endothelial dysfunction.
Why it matters
Vascular complications are the leading cause of death and disability in diabetes — damaging the heart, kidneys, eyes, and limbs. Current treatments manage blood sugar but do little to directly repair damaged blood vessels. This study suggests thymosin beta-4 could restore the repair capacity of diabetic endothelial cells, potentially offering a peptide-based approach to treating diabetic vascular disease that addresses the underlying cell dysfunction rather than just managing symptoms.
How the study worked
Researchers created endothelial cells from induced pluripotent stem cells (iPSCs) derived from diabetic patients (dia-hiPSC-ECs), providing a human disease model. They treated these cells with thymosin beta-4 at 600 ng/mL and measured proliferation, senescence, cell survival, protein expression (ICAM-1, Bcl-XL, AKT), secretion (endothelin-1, MMP-1), and mitochondrial function in vitro. For in vivo testing, they transplanted Tβ4-treated diabetic endothelial cells into a mouse model of type 2 diabetes with ischemic limb disease to assess angiogenic repair potential.
What this study cannot tell us
The in vitro work used iPSC-derived cells which, while patient-derived, may not perfectly replicate endothelial cells in a living body. The in vivo component used a mouse model of T2DM, which may not translate directly to human diabetic vascular disease. The study did not determine optimal dosing schedules, long-term effects, or address why Tβ4 failed to improve mitochondrial function and glycine homeostasis. No human clinical data was generated.
How to read the evidence
This is a preclinical study combining in vitro work with iPSC-derived cells and an in vivo mouse model. While using patient-derived cells adds clinical relevance, no human therapeutic data exists. The evidence supports a mechanistic rationale but is far from clinical proof of efficacy.
When this study was published
Published in 2022, this is a relatively recent study. iPSC-based disease modeling is a rapidly advancing field, and the combination with peptide therapy represents current research frontiers in regenerative medicine.
The bigger picture
Thymosin beta-4 is one of the most studied regenerative peptides, known for promoting wound healing, cell migration, and anti-inflammatory effects. This study extends its potential into a major clinical need — diabetic vascular disease. By using patient-derived iPSC technology, the researchers created a model that closely mirrors real diabetic endothelial dysfunction, making the findings more clinically relevant than standard cell line experiments. The combination of stem cell therapy and peptide treatment represents an emerging frontier in regenerative medicine for diabetes.
Questions still open
- Could thymosin beta-4 be administered directly to diabetic patients to improve blood vessel repair without the need for stem cell transplantation?
- Why did Tβ4 fail to improve mitochondrial function in diabetic endothelial cells, and could combination therapies address this gap?
- What is the optimal dosing and route of administration for Tβ4 to achieve vascular benefits in human diabetes?
Common questions
What is thymosin beta-4 and how does it help diabetic blood vessels?
Could this lead to a treatment for diabetic vascular disease?
Read the original research
Thymosin beta-4 improves endothelial function and reparative potency of diabetic endothelial cells differentiated from patient induced pluripotent stem cells.
Stem cell research & therapy, 13(1), 13
Citation
Su, Liping; Kong, Xiaocen; Loo, Szejie; Gao, Yu; Liu, Bingli; Su, Xiaofei; Dalan, Rinkoo; Ma, Jianhua; Ye, Lei. (2022). Thymosin beta-4 improves endothelial function and reparative potency of diabetic endothelial cells differentiated from patient induced pluripotent stem cells.. Stem cell research & therapy, 13(1), 13. https://doi.org/10.1186/s13287-021-02687-x